Polyclonal Antibody to SRSF Protein Kinase 3 (SRPK3)
| Code | Size | Price |
|---|
| PAQ342Mu01-20ul | 20ul | £94.00 |
Quantity:
| PAQ342Mu01-100ul | 100ul | £179.00 |
Quantity:
| PAQ342Mu01-200ul | 200ul | £243.00 |
Quantity:
| PAQ342Mu01-1ml | 1ml | £561.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
STK23; MSSK1; Serine/Threonine Kinase 23; SFRS Protein Kinase 3; Serine/arginine-rich protein-specific kinase 3; Muscle-specific serine kinase 1
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
SRSF Protein Kinase 3
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunofluorescence:5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunofluorescence:5-20ug/mL;
Optimal working dilutions must be determined by end user.
References
https://www.researchsquare.com/article/rs-1207279/latest.pdf;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant SRSF Protein Kinase 3 (SRPK3) | RPQ342Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||